AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 2Trial registry
Human Study on PIPE-307 for Relapsing-Remitting Multiple Sclerosis
A Phase 2 interventional study involving 182 subjects evaluated the safety of PIPE-307 compared to a placebo. Participants underwent assessments for treatment-emergent adverse events over 26 weeks.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This research is significant as it aims to establish the safety profile of PIPE-307 in treating relapsing-remitting multiple sclerosis, contributing to ongoing efforts to find effective therapeutics for this condition.
What this does not prove
No results have been posted, and the endpoints and planned enrollment do not provide conclusive findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 182 · Actual
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (12)
study phase"phases": [ "PHASE2" ]
study design"studyType": "INTERVENTIONAL"
subjects"briefSummary": "This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis.
sample size"count": 182
sample size basis"type": "ACTUAL"
randomized"allocation": "RANDOMIZED"
controlled"type": "PLACEBO_COMPARATOR"
regulatory approval"isFdaRegulatedDrug": true
primary endpoint"measure": "Treatment-emergent adverse events (TEAE)"
follow up"timeFrame": "From baseline to week 26 (end of treatment period)"
findings"briefSummary": "This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis.
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.